总生存期整体比较无统计学意义。
OS: P value demonstrated does not have the significance statistics difference.
总生存期将在会议期间提交。
Overall survival will be presented at the time of the meeting.
主要终点指标为总生存期，资料分析采用意向处理分析。
The primary endpoint was overall survival, and analysis was done by intention to treat.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
【译】在转移性结直肠癌影响总生存期KRAS测试吗？
Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival?
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
首要观察终点从总生存期(OS)改为无进展生存期(PFS)。
The primary end point was amended from overall survival (OS) to progression-free survival (PFS).
次要终点包括IRC评估的总生存期(OS)和总缓解率(ORR)。
Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC.
目的观察剂量密度化疗治疗乳腺癌的不良反应及对无病生存期和总生存期的影响。
Objective to investigate the adverse effect, disease free survival and overall survival of dose-dense chemotherapy in postoperative breast cancer patients.
主要指标是总生存期，次要指标包括无进展生存期(PFS)和客观反应率(ORR)。
The primary endpoint was overall survival, and secondary endpoints included PFS and objective response rate (ORR).
但中位总生存期，次要观察终点，联合组为20.5个月，而单药治疗组为20.6个月。
But median overall survival, a secondary end point, was 20.5 months in the combination group and 20.6 months in the monotherapy group.
次要观察终点包括总生存期，安全性，患者对治疗设施的满意度和理解以及医疗资源的利用。
Secondary endpoints included overall survival, safety, patients' satisfaction with and perception of treatment convenience, and medical resource utilization.
结果：FOXP3在肿瘤细胞中的表达与较差的总生存期有关，而且增加了FOXP3免疫染色强度。
Results: FOXP3 expression in tumors was associated with worse overall survival probability and the risk increased with increasing FOXP3 immunostaining intensity.
欧美权威机构接受PFS作为观察终点，而非总生存期（OS），肾细胞癌作为贝伐单抗的适应症范围。
PFS, rather than overall survival (OS), was accepted by regulatory authorities in the United States and Europe as the endpoint for approval of bevacizumab for the renal cell carcinoma indication.
结论：我们对边缘区淋巴瘤的研究是已报道的研究中规模最大的之一，结论是边缘区淋巴瘤总体预后良好，中位总生存期超过19年。
Conclusions: In our MZL series, one of the largest reported, prognosis of MZL is good with a median OS of over 19 years.
二级终点包含了目标反应率，一年生存期，总生存率，化疗类型和安全性PFS评估。
Secondary endpoints included objective response rate, one-year survival rate, overall survival, PFS assessment by chemotherapy type and safety.
生存中值反映了生存曲线上的一个时间点，并不能测量总的生存期。
Median survival reflects one time point along the survival curve and does not measure the overall survival benefit.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
应用推荐